Multiple sclerosis

Insights into vaccine readiness for people with MS on cladribine

Sponsored by Merck Healthcare Pty Ltd

A recent retrospective analysis of data from the MAGNIFY-MS study1 indicates that people with multiple sclerosis (MS) treated with cladribine are able to mount a protective immune response after influenza and varicella zoster vaccination, regardless of the timing of the vaccine relative to the cladribine dose and independent of lymphocyte counts. According to MAGNIFY-MS steering ...

Already a member?

Login to keep reading.

© 2021 the limbic